SAN
DIEGO, April 26, 2022 /PRNewswire/ -- Evofem
Biosciences, Inc., (Nasdaq: EVFM) today
announced it will present new data from the Phase 3 AMPOWER
Clinical Trial at the 2022 American College of Obstetricians and
Gynecologists (ACOG) annual meeting. The poster presentation
details the characterization of women who experienced urinary tract
infections (UTIs) during the AMPOWER Study.
"We look forward to presenting our poster at ACOG this year as
we continue our efforts to improve the sexual and reproductive
health of women," said Katherine
Atkinson, Chief Commercial Officer at Evofem. "Evofem's
presence at ACOG will extend from the poster floor to the Evofem
booth and product theatre, where we look forward to providing more
information about our research to healthcare providers."
Evofem will present the following poster at ACOG
2022:
Characterization of
Women Who Experienced
Urinary Tract Infections in the Phase 3
AMPOWER Trial
|
E-POSTER
Saturday, May 7, 2022
2:15 PM - 3:15
PM
Session Number
A015
|
Evofem will also host a product theatre at ACOG 2022 led by
Jennifer Broad, MD, about the first
and only FDA-approved, on-demand, nonhormonal contraceptive gel to
prevent pregnancy.
Evofem Product Theatre at ACOG 2022:
A New Category of Birth
Control: On-Demand
and Hormone Free
|
Friday, May 6,
2022
7:00 AM - 7:45
AM
Room 6C
Session Number PT02
|
About Evofem Biosciences
Evofem Biosciences, Inc. (Nasdaq: EVFM) is developing and
commercializing innovative products to address unmet needs in
women's sexual and reproductive health, including hormone-free,
woman-controlled contraception and protection from chlamydia and
gonorrhea. The Company's first FDA-approved
product, Phexxi® (lactic acid, citric acid, and potassium
bitartrate), is a hormone-free, on-demand prescription
contraceptive vaginal gel. It comes in a box of 12 pre-filled
applicators and is applied 0-60 minutes before each act of sex.
Learn more at phexxi.com and evofem.com.
Phexxi® is a registered trademark of Evofem Biosciences,
Inc.
Forward-Looking Statements
This press release includes "forward-looking statements" within the
meaning of the safe harbor for forward-looking statements provided
by Section 21E of the Securities Exchange Act of 1934, as amended,
and the Private Securities Litigation Reform Act of 1995. Various
factors could cause actual results to differ materially from those
discussed or implied in the forward-looking statements, including
market and other conditions, and you are cautioned not to place
undue reliance on these forward-looking statements, which are
current only as of the date of this press release. Each of these
forward-looking statements involves risks and uncertainties.
Important factors that could cause actual results to differ
materially from those discussed or implied in the forward-looking
statements, or that could impair the value of Evofem Biosciences'
assets, and business are disclosed in the Company's SEC filings,
including its Annual Report on Form 10-K for the year
ended December 31, 2021, filed with the SEC on March 10,
2022. All forward-looking statements are expressly qualified in
their entirety by such factors. The Company does not undertake any
duty to update any forward-looking statement except as required by
law.
Media Contact
Jack Hirschfield
Evofem Biosciences, Inc.
jhirschfield@evofem.com
(512) 674-5163
Investor Relations Contact
Amy Raskopf
Evofem Biosciences, Inc.
araskopf@evofem.com
(917) 673-5775
View original content to download
multimedia:https://www.prnewswire.com/news-releases/evofem-to-present-new-research-in-gynecological-health-at-the-2022-american-college-of-obstetricians-and-gynecologists-annual-meeting-301532521.html
SOURCE Evofem Biosciences, Inc.